Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients
Authors/Creators
-
Anna Lucia Tornesello1
- Chiara Botti2
- Alberto Micillo2
- Francesco Labonia3
- Sergio Arpino3
- Maria Antonietta Isgrò3
- Serena Meola3
- Luigi Russo3
- Ernesta Cavalcanti3
- Silvia Sale4
- Carmine Nicastro4
- Luigi Atripaldi4
- Noemy Starita1
- Andrea Cerasuolo1
- Ulf Reimer5
- Pavlo Holenya5
- Luigi Buonaguro6
- Franco M. Buonaguro1
- Maria Lina Tornesello1
- 1. Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Napoli, Italy
- 2. A.O.R.N. Santobono-Pausilipon, Napoli Italy
- 3. Laboratory Medicine Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Napoli, Italy
- 4. UOC Biochimica Chimica, AORN Ospedale dei Colli P.O. Monaldi, Napoli, Italy
- 5. JPT Peptide Technologies GmbH, Berlin. Germany
- 6. Innovative Immunological Models, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", via Mariano Semmola, 80131 Napoli, Italy
Description
Background: The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical course with some patients being asymptomatic whereas others experiencing severe respiratory distress, or even death. We aimed to evaluate the immunoglobulin G (IgG) response towards linear peptides on a peptide array containing sequences from SARS-CoV-2, Middle East respiratory syndrome-related coronavirus (MERS) and common-cold coronaviruses 229E, OC43, NL63 and HKU1 antigens, in order to identify immunological indicators of disease outcome in SARS-CoV-2 infected patients.
Methods: We included in the study 79 subjects, comprising 19 pediatric and 30 adult SARS-CoV-2 infected patients with increasing disease severity, from mild to critical illness, and 30 uninfected subjects who were vaccinated with one dose of SARS-CoV-2 spike mRNA BNT162b2 vaccine. Serum samples were analyzed by a peptide microarray containing 5,828 overlapping 15-mer synthetic peptides corresponding to the full SARS-CoV-2 proteome and selected linear epitopes of spike (S), envelope (E) and membrane (M) glycoproteins as well as nucleoprotein (N) of MERS, SARS and coronaviruses 229E, OC43, NL63 and HKU1 (isolates 1, 2 and 5).
Results: All patients exhibited high IgG reactivity against the central region and C-terminus peptides of both SARS-CoV-2 N and S proteins. Setting the threshold value for serum reactivity above 25,000 units, 100% and 81% of patients with severe disease, 36% and 29% of subjects with mild symptoms, and 8% and 17% of children younger than 8-years reacted against N and S proteins, respectively. Overall, the total number of peptides in the SARS-CoV-2 proteome targeted by serum samples was much higher in children compared to adults. Notably, we revealed a differential antibody response to SARS-CoV-2 M peptides between adults, mainly reacting against C-terminus M antigens, and children, which were highly responsive to N-terminus M epitopes. In addition, IgG signals against NS7B, NS8 and ORF10 peptides were found elevated mainly among adults with mild (63%) symptoms. Antibodies towards S and N proteins of other coronaviruses (MERS, 229E, OC43, NL63 and HKU1) were detected in all groups without a significant correlation with SARS-CoV-2 antibody levels.
Conclusions: Overall, our results showed that antibodies elicited by specific linear epitopes of SARS-CoV-2 proteome are age dependent and related to COVID-19 clinical severity. Cross-reaction of antibodies to epitopes of other human coronaviruses was evident in all patients with distinct profiles between children and adult patients. Several SARS-CoV-2 peptides identified in this study are of particular interest for the development of vaccines and diagnostic tests to predict the clinical outcome of SARS-CoV-2 infection.
Files
2023-Journal of translational medicine.pdf
Files
(6.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:9dc61b7c77c8c1830f2db7169fb1e68e
|
1.6 MB | Preview Download |
|
md5:9fa51a8a54a3c3a8f63471a1e69fa261
|
1.3 MB | Preview Download |
|
md5:465ce430d3826db5da93b7dbc113d767
|
205.9 kB | Preview Download |
|
md5:408b6c2dc0b8338fd0dee1ff26ac8509
|
491.3 kB | Preview Download |
|
md5:3d720f0096d667099cf856dd419e8695
|
216.5 kB | Preview Download |
|
md5:6d0e134700ce8b1434549b64246a1373
|
441.0 kB | Preview Download |
|
md5:6508613634ca5e4e050b3d3bff41b650
|
478.8 kB | Preview Download |
|
md5:53cc0c464ff989789de38a533aee3572
|
434.4 kB | Preview Download |
|
md5:84d1678ad5abd94c635bca5d84152471
|
610.5 kB | Preview Download |
|
md5:6aee8c5d9c0936a425d98c9bca856fa7
|
433.1 kB | Preview Download |
|
md5:501356ad9e46a7689c0c9cf74233223c
|
420.9 kB | Preview Download |